Literature DB >> 2988429

Mutually exclusive inhibition of herpesvirus DNA polymerase by aphidicolin, phosphonoformate, and acyclic nucleoside triphosphates.

K B Frank, Y C Cheng.   

Abstract

Dual inhibitor studies were performed to examine the interaction of aphidicolin, phosphonoformate, 9-(2-hydroxyethoxymethyl)guanine triphosphate, and 9-(1,3-dihydroxy-2-propoxymethyl)guanine triphosphate with herpes simplex virus DNA polymerase. Kinetic data indicated that inhibition by one agent prevents simultaneous inhibition by a second agent, producing a mutually exclusive inhibition pattern. This suggested that binding sites on the DNA polymerase molecule for these compounds are kinetically overlapping. These findings should be taken into consideration for the design of future antiviral compounds and combination chemotherapy protocols.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2988429      PMCID: PMC180071          DOI: 10.1128/AAC.27.4.445

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  Inhibition of herpesvirus replication and herpesvirus-induced deoxyribonucleic acid polymerase by phosphonoformate.

Authors:  J M Reno; L F Lee; J A Boezi
Journal:  Antimicrob Agents Chemother       Date:  1978-02       Impact factor: 5.191

2.  Herpes simplex virus type I DNA polymerase. Kinetic properties of the associated 3'-5' exonuclease activity and its role in araAMP incorporation.

Authors:  D Derse; Y C Cheng
Journal:  J Biol Chem       Date:  1981-08-25       Impact factor: 5.157

3.  Resistance of herpes simplex virus to acycloguanosine--genetic and physical analysis.

Authors:  C S Crumpacker; P Chartrand; J H Subak-Sharpe; N M Wilkie
Journal:  Virology       Date:  1980-08       Impact factor: 3.616

4.  Mechanism of inhibition of herpes simplex virus and vaccinia virus DNA polymerases by aphidicolin, a highly specific inhibitor of DNA replication in eucaryotes.

Authors:  G Pedrali-Noy; S Spadari
Journal:  J Virol       Date:  1980-11       Impact factor: 5.103

5.  Inhibition of herpes simplex virus-induced DNA polymerase activity and viral DNA replication by 9-(2-hydroxyethoxymethyl)guanine and its triphosphate.

Authors:  P A Furman; M H St Clair; J A Fyfe; J L Rideout; P M Keller; G B Elion
Journal:  J Virol       Date:  1979-10       Impact factor: 5.103

6.  Mechanism of phosphonoacetate inhibition of herpesvirus-induced DNA polymerase.

Authors:  S S Leinbach; J M Reno; L F Lee; A F Isbell; J A Boezi
Journal:  Biochemistry       Date:  1976-01-27       Impact factor: 3.162

7.  Novel interaction of aphidicolin with herpes simplex virus DNA polymerase and polymerase-associated exonuclease.

Authors:  K B Frank; D D Derse; K F Bastow; Y C Cheng
Journal:  J Biol Chem       Date:  1984-11-10       Impact factor: 5.157

8.  Resistance of herpes simplex virus to acycloguanosine: role of viral thymidine kinase and DNA polymerase loci.

Authors:  L E Schnipper; C S Crumpacker
Journal:  Proc Natl Acad Sci U S A       Date:  1980-04       Impact factor: 11.205

9.  Pyrophosphate analogues as inhibitors of herpes simplex virus type 1 DNA polymerase.

Authors:  B Eriksson; A Larsson; E Helgstrand; N G Johansson; B Oberg
Journal:  Biochim Biophys Acta       Date:  1980-03-28

10.  Physical mapping of drug resistance mutations defines an active center of the herpes simplex virus DNA polymerase enzyme.

Authors:  K W Knopf; E R Kaufman; C Crumpacker
Journal:  J Virol       Date:  1981-09       Impact factor: 5.103

View more
  12 in total

Review 1.  Resistance of herpesviruses to antiviral drugs.

Authors:  P A Chatis; C S Crumpacker
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

2.  Identification and some properties of a unique DNA polymerase from cells infected with human B-lymphotropic virus.

Authors:  A R Bapat; A J Bodner; R C Ting; Y C Cheng
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

3.  Identification of amino acids in herpes simplex virus DNA polymerase involved in substrate and drug recognition.

Authors:  J S Gibbs; H C Chiou; K F Bastow; Y C Cheng; D M Coen
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

4.  Inhibition of human immunodeficiency virus reverse transcriptase by 2',3'-dideoxynucleoside triphosphates: template dependence, and combination with phosphonoformate.

Authors:  M C Starnes; Y C Cheng
Journal:  Virus Genes       Date:  1989-05       Impact factor: 2.332

5.  Interaction between ganciclovir and foscarnet as inhibitors of duck hepatitis B virus replication in vitro.

Authors:  G Civitico; T Shaw; S Locarnini
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

Review 6.  Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis.

Authors:  P Chrisp; S P Clissold
Journal:  Drugs       Date:  1991-01       Impact factor: 9.546

7.  Genetic characterization of the vaccinia virus DNA polymerase: identification of point mutations conferring altered drug sensitivities and reduced fidelity.

Authors:  J A Taddie; P Traktman
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

8.  Delayed treatment with combinations of antiviral drugs in mice infected with herpes simplex virus and application of the median effect method of analysis.

Authors:  R F Schinazi; T C Chou; R T Scott; X J Yao; A J Nahmias
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

9.  Interaction of Epstein-Barr virus DNA polymerase with aphidicolin, phosphonoformate and 5'-GMP.

Authors:  J S Li; Y C Cheng
Journal:  Virus Genes       Date:  1988-07       Impact factor: 2.332

10.  Sequence and mapping analyses of the herpes simplex virus DNA polymerase gene predict a C-terminal substrate binding domain.

Authors:  J S Gibbs; H C Chiou; J D Hall; D W Mount; M J Retondo; S K Weller; D M Coen
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.